Mike Palazzolo
YOU?
Author Swipe
Supplementary Figure S4 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 4. Target T-cells do not undergo complement dependent cytotoxicity (CDC).
Supplementary Figure S3 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 3: Vβ monoclonal antibodies induce antibody dependent cellular cytotoxicity of target cells.
Supplementary Figure S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S1. Immunophenotype of Patient’s T-LGL cells.
Supplementary Methods S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Methods
Data from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Purpose: Targeted therapeutics are a goal of medicine. Methods for targeting T-cell lymphoma lack specificity for the malignant cell, leading to elimination of healthy cells. The T-cell receptor (TCR) is designed for antigen recognition. T…
Supplementary Figure S5 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 5. αVβ monoclonal antibodies induce target T-cell activation, characterized by down modulation of the TCR complex
Supplementary Methods S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Methods
Supplementary Table S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Table S1. (A) List of published datasets used to compile the distribution of TCRVB Gene Usage across T-cell NHL. (B) TCR Vβ usage in 314 patients with T-cell NHL by disease type. Note that both the IMGT and Wei et al nomencla…
Supplementary Figure S4 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 4. Target T-cells do not undergo complement dependent cytotoxicity (CDC).
Supplementary Figure S5 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 5. αVβ monoclonal antibodies induce target T-cell activation, characterized by down modulation of the TCR complex
Supplementary Figure S3 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 3: Vβ monoclonal antibodies induce antibody dependent cellular cytotoxicity of target cells.
Supplementary Figure S2 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S2: The binding specificity of αVβ monoclonal antibodies.
Supplementary Figure S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S1. Immunophenotype of Patient’s T-LGL cells.
Supplementary Table S1 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Table S1. (A) List of published datasets used to compile the distribution of TCRVB Gene Usage across T-cell NHL. (B) TCR Vβ usage in 314 patients with T-cell NHL by disease type. Note that both the IMGT and Wei et al nomencla…
Supplementary Figure S2 from Patient Specific Targeting of the T-cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S2: The binding specificity of αVβ monoclonal antibodies.
Supplementary Figure S5 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 5. αVβ monoclonal antibodies induce target T-cell activation, characterized by down modulation of the TCR complex
Supplementary Methods S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Methods
Supplementary Figure S2 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S2: The binding specificity of αVβ monoclonal antibodies.
Supplementary Figure S4 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 4. Target T-cells do not undergo complement dependent cytotoxicity (CDC).
Supplementary Figure S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S1. Immunophenotype of Patient’s T-LGL cells.
Supplementary Figure S4 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 4. Target T-cells do not undergo complement dependent cytotoxicity (CDC).
Supplementary Figure S5 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 5. αVβ monoclonal antibodies induce target T-cell activation, characterized by down modulation of the TCR complex
Data from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Purpose:Targeted therapeutics are a goal of medicine. Methods for targeting T-cell lymphoma lack specificity for the malignant cell, leading to elimination of healthy cells. The T-cell receptor (TCR) is designed for antigen recognition. T-…
Supplementary Figure S2 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S2: The binding specificity of αVβ monoclonal antibodies.
Supplementary Table S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Table S1. (A) List of published datasets used to compile the distribution of TCRVB Gene Usage across T-cell NHL. (B) TCR Vβ usage in 314 patients with T-cell NHL by disease type. Note that both the IMGT and Wei et al nomencla…
Supplementary Figure S3 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 3: Vβ monoclonal antibodies induce antibody dependent cellular cytotoxicity of target cells.
Supplementary Table S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Table S1. (A) List of published datasets used to compile the distribution of TCRVB Gene Usage across T-cell NHL. (B) TCR Vβ usage in 314 patients with T-cell NHL by disease type. Note that both the IMGT and Wei et al nomencla…
Supplementary Figure S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure S1. Immunophenotype of Patient’s T-LGL cells.
Supplementary Figure S3 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Figure 3: Vβ monoclonal antibodies induce antibody dependent cellular cytotoxicity of target cells.
Supplementary Methods S1 from Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases Open
Supplementary Methods